Article/February 27, 2024/6 mins

An unaffordable mess

Who’s to blame for America’s drug pricing crisis? It’s election year, and a prominent jewel in America’s economic crown—its pharma industry—is a front-and-center attraction.  Only, it’s less of a jewel,…

Article/August 12, 2026/2 mins

Challenging the diagnosis

Listen to the evidence “It is a capital mistake to theorise before one has data. Insensibly one begins to twist facts to suit theories, instead of theories to suit facts.”…

Article/July 29, 2026/2 mins

The Missing Patient

Where’s the humanity? ‘Patients aren’t data, they’re people’: it’s the stuff of a thousand cliched LinkedIn posts. There is power in segmented personas, maps and data points, but we know…

Article/July 22, 2026/4 mins

The Usual Symptoms

The Sieve of Reasonability Pharma isn’t short of great ideas, but the best ones are never realised. This is because, before they get to the field, they must pass through…

Article/July 22, 2026/3 mins

Rewarding Failure

Why we reward failure A pharma company likes to call itself scientific. But that’s not true. Or at least, it’s only true in one part of the company. The lab.…

Article/July 13, 2026/2 mins

Day Three

Every wellness retreat has the same design flaw. You spend some days in the mountains, breathing properly for the first time in a year, having the kind of conversation with…

Article/July 8, 2026/2 mins

Who will heal the healer?

Pharma has a track record of achieving the impossible. Vaccines, ADCs, gene therapy, even previously ‘hopeless’ disease areas like dementia: we’re making blinding progress in many areas.  In this context,…

View all articles